Understanding Fetal DNA Movement in Maternal Blood Improves Prenatal Screening Accuracy

An international research team led by Adelaide University has analyzed decades of research to better understand how fetal DNA enters and circulates in maternal blood, with implications for improving noninvasive prenatal testing accuracy. Current prenatal screening detects genetic conditions through placental DNA fragments but produces false alarms in 47 percent of high-risk cases, requiring invasive confirmation procedures. Improved understanding of fetal DNA packaging and transport mechanisms could enhance test reliability and reduce unnecessary stress and medical interventions for families.

Noninvasive prenatal testing emerged as a breakthrough screening method over a decade ago, offering expectant parents a safer alternative to invasive procedures that carry miscarriage risks. The test analyzes placental DNA fragments present in maternal circulation to identify chromosomal abnormalities. However, its practical utility remains constrained by a significant limitation: nearly half of positive results prove incorrect, forcing families into additional waiting periods and invasive confirmatory procedures like amniocentesis.

The Adelaide University-led research team focused on fundamental biological gaps that have persisted despite rapid technological advancement. Their analysis centered on determining which placental cells release fetal DNA, whether it exists as free fragments or bound to cellular structures like extracellular vesicles, and how these mechanisms affect the proportion of fetal genetic material available for testing—a measurement called fetal fraction that directly influences detection reliability.